<DOC>
	<DOCNO>NCT00272090</DOCNO>
	<brief_summary>The primary purpose protocol demonstrate new regimen ( insulin glargine+regular insulin ) bad reference regimen ( insulin glargine+lys-pro insulin ) reduce incidence severe nocturnal hypoglycemia end point ; secondary purpose compare two study regimen far glycemic control ( measure HbA1c ) , daily Mean Blood Glucose ( MBG ) mean amplitude glycemic excursion ( MAGE index ) , calculate basis Self Monitoring Blood Glugose ( SMBG ) data , concerned verify safety basal insulinization Lantus .</brief_summary>
	<brief_title>Insulin Glargine Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Subjects type 1 diabetes mellitus three year Subjects multiple daily injection insulin therapy , basalbolus scheme therapy HbA1c &lt; = 9 % ( measured central Lab , DCCT align standard method ) Fasting CPeptide &lt; = 0,1nmol/L FBG &gt; 126 mg/dl Body Mass Index ( BMI ) &lt; 30 kg/m2 Willingness accept intensive insulin therapy Ability willingness perform SMBG use plasma glucose meter Female subject must postmenopausal adequate contraception judge investigator ( may oral contraceptive , intrauterine device surgical treatment ) must negative serum pregnancy test Exclusion criterion : Diabetes type 1 diabetic mellitus Type 1 diabetic patient total insulin dose &gt; = 1 IU/kg/day Serum creatinine &gt; 1.5 mg/dl , history renal transplantation current renal dialysis Congestive heart failure NYHA class II Acute chronic metabolic acidosis , include diabetic ketoacidosis Clinical evidence active liver disease , serum ALT/AST 2 time upper limit normal range Hypoglycemia unawareness Pregnancy lactation Concomitant use Î²blockers , thiazide systemic corticosteroid More one episode severe hypoglycemia seizure coma past year Likelihood require treatment study period antidiabetic drug study drug Failure use adequate contraception ( woman current reproductive potential ) Known hypersensitivity insulin glargine , excipients Malignancy except basal cell carcinoma within last five year Long last ( &gt; 2 week ) treatment systemic glucocorticoid therapy Known adrenal insufficiency ( interfere hypoglycemia counterregulation ) Known hemoglobinopathy chronic anemia may interfere Hb1Ac determination History substance alcohol abuse within last two year current addiction substance abuse include ethanol History positive HIV test Hepatitis B/C test Any usage outside current SPC ( Summary Product Characteristics ) Any clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease type 1 diabetic mellitus make implementation protocol interpretation study result difficult History demonstrable micro macroangiopathic complication Preplanned surgery study Blood donation 500 ml previous 3 month male 6 month female Smoker previous 3 month Receipt experimental drug use experimental device within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>